Everest Medicines mRNA ambitions have a new pair of leaders: the company has appointed two scientists who previously worked at Moderna to strengthen its cancer-vaccine and translational research. The announcement, dated 9 October 2026, names Lakshmi Srinivasan as senior vice president and head of translational medicine, and Brandon Coder as vice president of translational sciences and discovery.
Hires like these rarely change a pipeline overnight, but they show where a company wants to build. This article explains who the two appointees are, what Everest is developing, and what the move does and does not tell us.
Everest Medicines mRNA hires: key points
- Lakshmi Srinivasan, PhD: senior vice president and head of translational medicine.
- Brandon Coder, PhD: vice president, translational sciences and discovery.
- Background: both come from Moderna, where they worked on oncology and cancer vaccines until 2025.
- Purpose: to advance the company’s proprietary mRNA platform and pipeline, per Everest.
- Not disclosed: compensation, start dates and locations.
Who the new Everest Medicines mRNA leaders are
Dr Srinivasan was executive director and head of oncology translational medicine at Moderna from 2023 to 2025. Earlier roles included Repertoire Immune Medicines, Neon Therapeutics, which BioNTech has since acquired, and Sanofi’s oncology unit.
Dr Coder worked at Moderna from 2019 to 2025 and finished as associate scientific director of cancer vaccine research. Before that, he was associate director of immuno-oncology research at Advaxis Immunotherapies.
Translational medicine is the bridge between laboratory discoveries and human trials. It covers choosing targets, picking biomarkers and designing early studies, so both appointments sit at a key decision point for a cancer vaccine pipeline.
What translational leadership does in a vaccine pipeline
- Target choice: deciding which tumour proteins or mutations a vaccine should aim at.
- Biomarkers: picking the blood or tissue signals that show whether the immune system is responding.
- Trial design: setting doses, patient groups and combinations with other cancer drugs, such as checkpoint inhibitors.
- Evidence for regulators: shaping the data package that agencies will ask for.
These tasks are less visible than laboratory discoveries, but mistakes in them can sink an otherwise promising candidate. That is why companies often pay a premium for people who have already run such programmes elsewhere.
What Everest Medicines mRNA programmes are in development
The company’s announcement points to two cancer-vaccine candidates, which we describe below as Everest does.
- EVM14: an off-the-shelf mRNA vaccine targeting tumour-associated antigens, which are proteins found at higher levels on cancer cells. Everest says the Phase I study is nearing completion in early 2027.
- EVM16: a personalised mRNA therapeutic cancer vaccine, with a Phase Ib trial planned.
An off-the-shelf vaccine uses the same ingredients for every patient. A personalised vaccine is built from the genetic profile of an individual’s tumour, which is more complex to make but may match the tumour more closely. The two approaches are being pursued by several companies, including Moderna and Merck, which are developing an individualised neoantigen therapy.
Personalised vaccines raise a practical question that translational teams must answer early: how fast can a vaccine be made for each patient? Tumour sequencing, design and manufacturing must fit within the window before a patient’s disease progresses. The announcement does not say how Everest plans to handle that step.
Why former Moderna talent matters to the Everest Medicines mRNA strategy
Moderna built the best-known mRNA platform and has years of experience running cancer-vaccine programmes. People who have worked on those programmes bring practical knowledge: how to select antigens, how to design dose-finding studies and how to deal with regulators. That experience is hard to buy through licensing alone.
The company’s chairman, Yifang Wu, said the appointments reflect continued investment in world-class talent and the global mRNA strategy. The announcement provides no further detail on how the roles will be split or where the new executives will work.
What the Everest Medicines mRNA announcement does not say
- Whether either programme has human efficacy data. Neither is described as having results.
- The cost of the hires or any share-based incentives.
- Trial locations or regulators involved.
- A timeline for starting EVM16’s Phase Ib study.
Early-stage cancer-vaccine candidates have a high failure rate, as is typical in oncology. The National Cancer Institute explains that therapeutic cancer vaccines are an area of active research and that few are approved. A new leader does not remove that risk.
Where Everest Medicines mRNA fits in the mRNA landscape
Interest in mRNA has broadened beyond infectious disease to gene editing, protein replacement and cancer. Our coverage of a Cas9 mRNA offering for gene-editing research shows mRNA as a tool, while an AI antibody discovery workflow and a solid-tumour preclinical candidate show how other companies are building oncology pipelines. In that context, Everest is a regional company seeking a global role.
Therapeutic vaccines of this type are overseen by regulators such as the US Food and Drug Administration (FDA), which reviews cellular and gene therapy products, and by agencies elsewhere. Company details are at Everest Medicines.
Our assessment of the Everest Medicines mRNA hires
In our assessment, the Everest Medicines mRNA hiring is a sensible, credible move for a company with two cancer-vaccine candidates that are about to move into later phases of early development. The strongest signal is the depth of cancer-vaccine experience brought in, not the titles. The weakest point is the lack of data: until Everest shows results from EVM14 or begins its EVM16 trial, the hires are a statement of intent.
For more biotech coverage, browse our biotechnology section.
What to watch next
- Completion and results of the EVM14 Phase I study, expected around early 2027.
- Start of the EVM16 Phase Ib trial.
- Further senior hires or partnerships in the Everest Medicines mRNA programme.
- Any disclosure of the company’s manufacturing plans for personalised vaccines.
Frequently asked questions
Who did Everest Medicines hire for its mRNA team?
Lakshmi Srinivasan as senior vice president and head of translational medicine, and Brandon Coder as vice president of translational sciences and discovery, both from Moderna.
What mRNA candidates does Everest have?
EVM14, an off-the-shelf tumour-associated antigen vaccine, and EVM16, a personalised cancer vaccine.
When will EVM14 finish Phase I?
Everest describes the study as nearing completion in early 2027.
Does the Everest Medicines mRNA team have any approved products?
The announcement does not describe any approved mRNA product.
Why does translational medicine matter?
It links laboratory science to clinical trials, deciding which targets and biomarkers to test in patients.
How we reported this: we based this article on Everest Medicines’ announcement of 9 October 2026. Descriptions of the candidates are the company’s. Background on Moderna and Merck is general public knowledge. Last updated: 12 October 2026. This article is news reporting and not investment advice.
